表紙
市場調査レポート

米国の皮膚置換/代用皮膚および活性創傷修復モジュレーター市場

U.S. Markets for Skin Replacements and Substitutes and Active Wound Repair Modulators

発行 Medtech Insight 商品コード 263762
出版日 ページ情報 英文 121 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
米国の皮膚置換/代用皮膚および活性創傷修復モジュレーター市場 U.S. Markets for Skin Replacements and Substitutes and Active Wound Repair Modulators
出版日: 2013年02月28日 ページ情報: 英文 121 Pages
概要

米国における培養皮膚置換/代用および活性創傷修復モジュレーターの売上は、2011年におよそ4億480万米ドルとなりました。皮膚置換/代用皮膚は売上の78.1%、活性創傷修復モジュレーターは残りの21.9%を占めました。同売上は今後、予測期間を通してCAGR6.3%で拡大し、2016年には5億4,970万米ドルに達すると推計されています。

当レポートでは、米国における皮膚置換/代用皮膚および活性創傷修復モジュレーター市場について調査し、製品、技術、市場の現況と予測、競合企業および機会の分析、創傷管理、培養皮膚置換/代用および活性創傷修復モジュレーターの臨床的課題の分析、主要企業のプロファイルなどをまとめ、概略以下の構成でお届けします。

エグゼクティブサマリー

第1章 創傷管理における臨床課題

  • 創縫合の生理学
  • 創縫合の影響因子
  • 創傷の種類

第2章 培養皮膚置換/代用

  • 同種移植片
  • 自家移植片
  • 異種移植片
  • 自家・培養皮膚置換/代用
    • 表皮同等製品
    • 真皮同等製品
    • 多層同等製品
  • 市場予測
  • 競合分析

第3章 活性創傷修復モジュレーター

  • 成長因子
    • 成長因子の分類
    • コンペティター・製品
    • 市場予測
  • 遺伝子治療薬
  • 幹細胞
    • 幹細胞の種類
    • 創傷治療における幹細胞の役割
    • 市況
  • その他の活性創傷修復モジュレーター・医薬品
    • 抗生物質・抗感染薬
    • ホルモン
    • マトリクスメタロプロテイナーゼ酵素阻害薬
    • 糖尿病性創傷における神経ペプチド
    • その他の製品

第4章 企業プロファイル

  • Biomet, Inc.
  • Forticell Bioscience, Inc.
  • Genentech, Inc./F. Hoffmann-La Roche LTD
  • Genzyme Corporation/Sanofi SA
  • Integra LifeSciences, Inc./Integra LifeSciences Holdings Corporation
  • LifeCell Corporation/Kinetic Concepts, Inc.
  • Organogenesis, Inc.
  • Smith & Nephew PLC
  • TEI Biosciences, Inc.

図表

目次
Product Code: A140

In 2011, U.S. sales of tissue-engineered skin replacements/substitutes and active wound repair modulators totaled approximately $404.8 million; of this, skin replacements/substitutes (including traditional products that are used for a broad range of indications including cosmetic and reconstructive surgery, as well as future introductions of tissue-engineered skin replacement/substitute products for a variety of wound healing applications) accounted for an estimated 78.1% of sales, and active wound repair modulators (consisting only of growth factors, the only FDA approved product in this market to date) accounted for the remaining 21.9% of sales. Over the forecast period covered by this report, combined sales are expected to increase at a compound annual rate of 6.3%, reaching an estimated $549.7 million in the year 2016.

This new report from Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities in the U.S. skin replacements/substitutes and active wound repair modulators market. Topics discussed in this report include an overview of clinical issues in wound management, tissue-engineered skin replacements/substitutes (e.g., epidermal equivalents, dermal equivalents, and multilayer equivalents), active wound repair modulators (e.g., growth factors, gene therapy agents, stem cells, antibiotics/anti-infectives, hormones, matrix metalloproteinase inhibitors, and neuropeptides), analyses of market forecasts and market shares, and profiles of leading competitors and products in these markets.

Table of Contents

EXECUTIVE SUMMARY

  • i. Tissue-Engineered Skin Replacements/Substitutes
  • ii. Active Wound Repair Modulators
    • a. Growth Factors
    • b. Gene Therapy
    • c. Stem Cells
  • iii. Combined Market Forecast
  • Exhibit ES-1: Tissue-Engineered Skin Replacements and Substitutes, Market Forecast, 2011-2016
  • Exhibit ES-2: Growth Factors, Market Forecast, 2011-2016
  • Exhibit ES-3: Tissue-Engineered Skin Replacements/Substitutes and Active Wound Repair Modulators, Combined Market Forecast, 2011-2016

1. CLINICAL ISSUES IN WOUND MANAGEMENT

  • 1.1. Physiology of Wound Closure
    • 1.1.1. Layers of the Skin and Supporting Structures
      • 1.1.1.1. Epidermis
      • 1.1.1.2. Dermis
      • 1.1.1.3. Hypodermis
      • 1.1.1.4. Fascia
      • 1.1.1.5. Muscle
      • 1.1.1.6. Bone
    • 1.1.2. Wound Closure Process
      • 1.1.2.1. Hemostasis
      • 1.1.2.2. Inflammation
      • 1.1.2.3. Proliferation
      • 1.1.2.4. Remodeling Phase
  • 1.2. Factors Affecting Wound Closure
    • 1.2.1. Intrinsic Factors
      • 1.2.1.1. Age and Chronic Illness
      • 1.2.1.2. Body Composition
      • 1.2.1.3. Nutritional Status
    • 1.2.2. Extrinsic Factors
      • 1.2.2.1. Ambient Temperature
      • 1.2.2.2. Desiccation/Hydration
      • 1.2.2.3. Infection
      • 1.2.2.4. Maceration
      • 1.2.2.5. Medication and Other Treatment Modalities
      • 1.2.2.6. Necrotic Tissue and Debris
      • 1.2.2.7. Oxygen
      • 1.2.2.8. Stress
      • 1.2.2.9. Wound Creation and Depth
      • 1.2.2.10. Wound Closure Techniques
      • 1.2.2.11. Other Extrinsic Factors
    • 1.2.3. Complications of Wound Healing
      • 1.2.3.1. Scarring
      • 1.2.3.2. Bleeding
  • 1.3. Wound Types
    • 1.3.1. Illness-Related Wounds
      • 1.3.1.1. Etiology
        • 1.3.1.1.1. Arterial Ulcers
        • 1.3.1.1.2. Diabetic Ulcers
        • 1.3.1.1.3. Venous Ulcers
      • 1.3.1.2. Epidemiology
    • 1.3.2. Pressure Ulcers
      • 1.3.2.1. Etiology
      • 1.3.2.2. Epidemiology
    • 1.3.3. Surgical Wounds
      • 1.3.3.1. Etiology
      • 1.3.3.2. Epidemiology
    • 1.3.4. Traumatic Wounds
      • 1.3.4.1. Etiology
        • 1.3.4.1.1. Abrasions, Contusions, and Lacerations
        • 1.3.4.1.2. Amputations
        • 1.3.4.1.3. Burns
      • 1.3.4.2. Epidemiology
  • Exhibit 1-1: The Skin's Layers and Supporting Structures
  • Exhibit 1-2: Phases of the Wound Closure Process
  • Exhibit 1-3: Intrinsic and Extrinsic Factors Affecting Wound Closure
  • Exhibit 1-4: Illness-Related Wounds, Facts and Figures, 1996-2006, and 2009
  • Exhibit 1-5: Pressure Ulcers, Facts and Figures, 1996-2006, and 2009
  • Exhibit 1-6: Stages of Pressure Ulcers
  • Exhibit 1-7: Surgical Wounds, Facts and Figures, 1996-2006, and 2009
  • Exhibit 1-8: Lacerations and Other Types of Traumatic Wounds, Facts and Figures, 1996-2006, and 2009
  • Exhibit 1-9: Amputations, Facts and Figures, 1996-2006, and 2009
  • Exhibit 1-10: Burns, Facts and Figures, 1996-2006, and 2009
  • Exhibit 1-11: Classification of Burns, by Mechanism of Injury
  • Exhibit 1-12: Classification of Burns, by Extent of Injury

2. TISSUE-ENGINEERED SKIN REPLACEMENTS AND SUBSTITUTES

  • 2.1. Allografts
  • 2.2. Autografts
  • 2.3. Xenografts
  • 2.4. Autologous and Tissue-Engineered Skin Replacements/Substitutes
    • 2.4.1. Epidermal Equivalent Products
    • 2.4.2. Dermal Equivalent Products
    • 2.4.3. Multilayer Equivalent Products
  • 2.5. Market Forecast
  • 2.6. Competitive Analysis
  • Exhibit 2-1: 2013, Selected Current and Emerging Tissue-Engineered Skin Replacements and Substitutes
  • Exhibit 2-2: Tissue-Engineered Skin Replacements and Substitutes, Market Forecast, 2011-2016
  • Exhibit 2-3: 2011, Tissue-Engineered Skin Replacements and Substitutes Market, Share by Supplier

3. ACTIVE WOUND REPAIR MODULATORS

  • 3.1. Growth Factors
    • 3.1.1. Growth Factor Classification
      • 3.1.1.1. Fibroblast Growth Factors
      • 3.1.1.2. Transforming Growth Factors
      • 3.1.1.3. Epidermal Growth Factors
      • 3.1.1.4. Platelet-Derived Growth Factors
      • 3.1.1.5. Insulin-Like Growth Factors
      • 3.1.1.6. Keratinocyte Growth Factors
      • 3.1.1.7. Vascular Endothelial Growth Factors
      • 3.1.1.8. Autologous Growth Factors
        • 3.1.1.8.1. Arteriocyte Medical Systems
        • 3.1.1.8.2. Biomet
        • 3.1.1.8.3. Cytomedix
        • 3.1.1.8.4. Harvest Technologies/Terumo
      • 3.1.1.9. Summary of Angiogenic Growth Factors
    • 3.1.2. Competitors and Products
    • 3.1.3. Market Forecast
  • 3.2. Gene Therapy Agents
  • 3.3. Stem Cells
    • 3.3.1. Types of Stem Cells
      • 3.3.1.1. Embryonic Stem Cells
      • 3.3.1.2. Adult Stem Cells
      • 3.3.1.3. Cord Blood Stem Cells
    • 3.3.2. The Role of Stem Cells in Wound Healing
    • 3.3.3. Market Status
  • 3.4. Other Active Wound Repair Modulators and Pharmaceuticals
    • 3.4.1. Antibiotics and Anti-Infectives
    • 3.4.2. Hormones
    • 3.4.3. Matrix Metalloproteinase Enzyme Inhibitors
    • 3.4.4. Neuropeptides in Diabetic Wounds
    • 3.4.5. Other Products
  • Exhibit 3-1: Selected Growth Factors in Development for Wound Healing Applications
  • Exhibit 3-2: The Angiogenesis Process
  • Exhibit 3-3: 2012, Selected Angiogenic Growth Factors
  • Exhibit 3-4: Growth Factors, Market Forecast, 2011-2016

4. COMPANY PROFILES

  • 4.1. Biomet, Inc.
  • 4.2. Forticell Bioscience, Inc.
  • 4.3. Genentech, Inc./F. Hoffmann-La Roche LTD
  • 4.4. Genzyme Corporation/Sanofi SA
  • 4.5. Integra LifeSciences, Inc./Integra LifeSciences Holdings Corporation
  • 4.6. LifeCell Corporation/Kinetic Concepts, Inc.
  • 4.7. Organogenesis, Inc.
  • 4.8. Smith & Nephew PLC
  • 4.9. TEI Biosciences, Inc.

APPENDIX: COMPANY LISTING

Back to Top